Trial Profile
Pilot Study to Assess the Efficacy and Safety of Switching Protease Inhibitor to Etravirine in HIV-1-infected Subjects With Viremia Suppression.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Dec 2021
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Acronyms ETRA-SWITCH
- 17 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 15 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Oct 2010 Planned patient number is 60 as reported by ClinicalTrials.gov.